![gram negative bacilli gram negative bacilli](https://pixnio.com/free-images/science/microscopy-images/plague-yersenia-pestis/yersinia-pestis-is-a-small-gram-negative-bacillus.jpg)
Patients in the neurology ICU were frequently infected with CLR MDR strains. In this study, co-morbidity was not found among 57.9% of the ICU patients and recovery was maximum i.e., 74.2%.Ĭonclusion: This study found the prevalence of colistin resistance to be high (19.6%) among all MDR GNB isolates from samples of ICU patients, Klebsiella pneumonia and Escherichia coli commonly acquire colistin resistance. CLR drug-resistant isolates were commonly (28.8%) isolated from samples of respiratory tract infections and the majority (54.1%) were from neurology ICU. Colistin resistance among the MDR isolates was found to be the highest (9.2% for Klebsiella pneumonia followed by 5% for Escherichia coli). Results: The prevalence of colistin resistance MDR GNB was found to be 19.6% in the present study. Clinical data was collected from hospital electronic medical records and presented as percentage, number (N), and median (range). MDR organisms were examined for colistin susceptibility by the broth dilution method. Samples collected for culture and sensitivity testing were processed as per standard guidelines in the microbiology laboratory. MDR GNB isolates from different clinical samples of ICU patients, not intrinsically resistant to colistin, were included in this study. Materials and methods: A prospective study was conducted in the ICU of a tertiary care hospital in Eastern Odisha, India from March 2019 to February 2020. The purpose of this study was to estimate the prevalence of colistin-resistance (CLR) in MDR isolates collected from different intensive care units (ICUs) and to determine the clinical outcomes of the patients. However, in the recent past, there has been a rise in colistin resistance among MDR isolates in clinical settings with no profound data on the incidences and causes. Introduction: Colistin is considered to be the last resort for the management of infections caused by multi-drug resistant (MDR) gram-negative bacilli (GNB).